These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16198199

  • 1. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J, Demily C, Thibaut F.
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [Abstract] [Full Text] [Related]

  • 2. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA, Morrens M, Sabbe BG.
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [Abstract] [Full Text] [Related]

  • 3. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR.
    J Clin Psychiatry; 1999 Sep; 60 Suppl 12():24-9. PubMed ID: 10372607
    [Abstract] [Full Text] [Related]

  • 4. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [Abstract] [Full Text] [Related]

  • 5. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [Abstract] [Full Text] [Related]

  • 6. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI, Miller AL.
    J Clin Psychiatry; 1999 Dec; 60 Suppl 23():25-8. PubMed ID: 10625197
    [Abstract] [Full Text] [Related]

  • 7. Treatment of cognitive deficits in schizophrenia.
    Bowie CR, Harvey PD.
    Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
    [Abstract] [Full Text] [Related]

  • 8. [Learning potential and cognitive remediation in schizophrenia].
    Raffard S, Gely-Nargeot MC, Capdevielle D, Bayard S, Boulenger JP.
    Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
    [Abstract] [Full Text] [Related]

  • 9. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A, Ritsner MS.
    Clin Neuropharmacol; 2008 Sep; 31(4):204-20. PubMed ID: 18670244
    [Abstract] [Full Text] [Related]

  • 10. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW.
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract] [Full Text] [Related]

  • 11. Ziprasidone and cognition: the evolving story.
    Harvey PD.
    J Clin Psychiatry; 2003 Jun; 64 Suppl 19():33-9. PubMed ID: 14728088
    [Abstract] [Full Text] [Related]

  • 12. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S.
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [Abstract] [Full Text] [Related]

  • 13. Executive functioning component mechanisms and schizophrenia.
    Kerns JG, Nuechterlein KH, Braver TS, Barch DM.
    Biol Psychiatry; 2008 Jul 01; 64(1):26-33. PubMed ID: 18549874
    [Abstract] [Full Text] [Related]

  • 14. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
    Ritsner MS, Strous RD.
    J Psychiatr Res; 2010 Jan 01; 44(2):75-80. PubMed ID: 19665142
    [Abstract] [Full Text] [Related]

  • 15. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL, Goldberg TE.
    Biol Psychiatry; 2004 May 15; 55(10):1013-22. PubMed ID: 15121486
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.
    Hum Psychopharmacol; 2009 Oct 15; 24(7):565-73. PubMed ID: 19790174
    [Abstract] [Full Text] [Related]

  • 18. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C, Dinan T.
    Hum Psychopharmacol; 2007 Aug 15; 22(6):397-406. PubMed ID: 17579928
    [Abstract] [Full Text] [Related]

  • 19. Socioaffective factors modulate working memory in schizophrenia patients.
    Park S, Gibson C, McMichael T.
    Neuroscience; 2006 Apr 28; 139(1):373-84. PubMed ID: 16337745
    [Abstract] [Full Text] [Related]

  • 20. [Correlation between cognitive defects and the course of schizophrenia. Initial study of a rehabilitation programme participants].
    Hanuszkiewicz I, Cechnicki A, Kalisz A.
    Psychiatr Pol; 2007 Apr 28; 41(4):539-50. PubMed ID: 18046984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.